



Why is global health R&D a smart investment for America?

US government (USG) investments in global health research and development (R&D) are a win-win from a humanitarian and strategic perspective. These investments save lives worldwide, while at the same time delivering health, economic, and security benefits for Americans.

Saves and improves lives worldwide

A new child friendly **malaria medicine** developed with USG support has **saved an estimated**

750,000

child lives

since its introduction in 2009.



+10 years

Antiretroviral therapies developed with USG support have increased life expectancy for Americans living with HIV/AIDS by **10 years.**



Fuels US economic growth and job creation

89¢

of every dollar the USG invests in global health R&D stays within the United States, **supporting American researchers.**



USG investment in global health R&D between 2007 and 2015 **generated an estimated:**

200K

 new US jobs

\$33

 in US economic growth.
BILLION

advancing **innovation** to save lives

Protects americans from health threats and **promotes** health security

- Zika and Ebola outbreaks highlight the consequences of underinvesting in R&D and waiting for an epidemic to trigger research: **We had no tools** in hand to prevent, diagnose, and treat these diseases.

1B

60B

- Pandemics could cost the world **\$60 billion a year**, while investing in the R&D needed to protect against outbreaks would cost **only \$1 billion a year.**

Saves money and **reduces** treatment costs



\$26M → \$180B

\$26 million invested in **polio vaccine** R&D has generated \$180 billion in treatment cost savings in the United States alone since the 1950s.



Vaccine vial monitors, which measure heat exposure to ensure vaccine potency, **have prevented \$140 million in waste** over the past decade.

Leverages private-sector investment

USG investments in global health R&D have a multiplier effect by stimulating investments from the private sector and de-risking research.

8 to 1 ratio multiplier effect



A single year of USG investment in basic research for global health will generate almost **\$4 billion in additional private-sector investment** over eight years.

Demonstrates America's character & **strengthens** US relationships abroad

- The average **US approval rating was 68%** in countries receiving PEPFAR support compared to the **global average of 46%**.
- **86% of Americans** think improving the health of people in developing countries should be an **important priority** for the United States.

Delivers outsized returns at minimal cost

The USG leads the world in global health R&D, investing **less than .01% of US GDP.**

